Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other Non-Current Assets: 2010-2024

Historic Other Non-Current Assets for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $117.0 million.

  • OptimizeRx's Other Non-Current Assets rose 3135911.6% to $113.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.9 million, marking a year-over-year increase of 3135911.6%. This contributed to the annual value of $117.0 million for FY2024, which is 919.13% down from last year.
  • OptimizeRx's Other Non-Current Assets amounted to $117.0 million in FY2024, which was down 919.13% from $128.9 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Other Non-Current Assets ranged from a high of $128.9 million in FY2023 and a low of $25.7 million during FY2021
  • Its 5-year average for Other Non-Current Assets is $67.0 million, with a median of $35.9 million in 2022.
  • Per our database at Business Quant, OptimizeRx's Other Non-Current Assets skyrocketed by 25866.55% in 2023 and then crashed by 919.13% in 2024.
  • Annual analysis of 5 years shows OptimizeRx's Other Non-Current Assets stood at $27.3 million in 2020, then decreased by 5.83% to $25.7 million in 2021, then skyrocketed by 39.68% to $35.9 million in 2022, then soared by 258.67% to $128.9 million in 2023, then fell by 9.19% to $117.0 million in 2024.
  • Its Other Non-Current Assets stands at $117.0 million for FY2024, versus $128.9 million for FY2023 and $35.9 million for FY2022.